A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
This trial is a retrospective, observational study, patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).
Resectable Pancreatic Cancer
DRUG: Nimotuzumab
overall survival (OSï¼‰, The primary endpoint is overall survival (OS), defined as the time from the start of surgery to the date of death due to any cause., approximately 84 months
disease-free survival (DFS), DFS is defined as the time from surgical resection to the first tumor recurrence/progression or death due to any cause., approximately 84 months|locoregional recurrence-free survival (LRRFS), LRRFS is defined as the time from surgical treatment to clinically or radiographically confirmed local recurrence and/or regional progression at follow-up., approximately 84 months
This trial is a retrospective, observational study based on real-world data obtained from the Health Information System (HIS) of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).